Abstract
Immunogenic cell death (ICD) is a modality of regulated cell death that is sufficient to promote an adaptive immune response against antigens of the dying cell in an immunocompetent host. An important characteristic of ICD is the release and exposure of damage-associated molecular patterns, which are potent endogenous immune adjuvants. As the induction of ICD can be achieved with conventional cytotoxic agents, it represents a potential approach for the immunotherapy of cancer. Here, different aspects of ICD in cancer biology and treatment are reviewed.
Author supplied keywords
Cite
CITATION STYLE
Rodrigues, M. C., Morais, J. A. V., Ganassin, R., Oliveira, G. R. T., Costa, F. C., Morais, A. A. C., … Muehlmann, L. A. (2022, August 1). An Overview on Immunogenic Cell Death in Cancer Biology and Therapy. Pharmaceutics. MDPI. https://doi.org/10.3390/pharmaceutics14081564
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.